Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Baxter
Manufacturing
FDA slams Eugia with Form 483 and posts several other reprimands
Aurobindo subsidiary Eugia US received an FDA Form 483 write-up following an inspection that turned up 10 observations at the company’s NJ facility.
Joseph Keenan
Jan 31, 2024 4:30pm
FDA signs off on Takeda's HyQvia as maintenance therapy for CIDP
Jan 16, 2024 11:12am
Glenmark, Baxter issue recalls for hypertension and cancer drugs
Aug 28, 2023 1:32pm
Intas and other manufacturers hit with FDA warning letters
Aug 2, 2023 9:55am
Baxter's for-sale CMO attracts Thermo Fisher, Celltrion: Reuters
Mar 21, 2023 11:19am
'The Top Line': FDA's drug approval, plus this week's headlines
Jan 13, 2023 6:00am